06998 GENOR-B
- 1.320
- -0.070-5.04%
GENOR-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
嘉和生物-B：2023年度報告
As a result of the exercise of share options, Jiahe Bio-B (06998.HK) issued 4.442,400 shares
Jiahe Bio-B (06998.HK) announced that on April 10, 2024, the company issued 4.442,400 shares due to the exercise of share options by director Guo Feng under the pre-initial public offering share option scheme.
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Jiahe Bio-B (06998) announced 2023 results. Losses attributable to owners of about 674 million yuan narrowed 7.65% year-on-year
Jiahe Bio-B (06998) announced its 2023 results. The total revenue was zero, and the 2022 revenue was about 159...
GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSED ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
China's Drug Regulator Accepts Genor Biopharma's New Breast Cancer Drug Application; Shares Up 7%
Genor Biopharma Holdings (HKG:6998) said China's National Medical Products Administration officially accepted its new drug application for GB491 combined with Letrozole for advanced breast cancer trea
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Jiahe Bio-B (06998.HK): China National Drug Administration accepted the marketing license application for a new drug of lerocilide hydrochloride tablets (GB491, Lerociclib)
Gelonghui, March 13, 丨 Jiahe Bio-B (06998.HK) announced that on March 13, 2024, the China National Drug Administration (“NMPA”) has officially accepted a new drug marketing license application (“NDA”) for patients with advanced breast cancer (GB491, Lerociclib) combined with letrozole to treat hormone receptor (HR) positive and negative human epidermal growth factor receptor 2 (HER2-) without prior systemic anti-tumor treatment. Previously, lerocilide hydrochloride tablets (GB491, Lerocicli
Jiahe Bio-B (06998.HK) will hold a board meeting on March 27 to approve the full year results
Gelonghui March 13 | Jiahe Bio-B (06998.HK) issued an announcement. The board of directors of the company will hold a board meeting on March 27, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
GENOR-B: DATE OF BOARD MEETING
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Express News | Connbey: Net profit of 2023 is expected to increase 65% to 90% year-on-year from 233 million yuan to 322 million yuan
Jiahe Bio-B (06998) issues 285,000 shares due to the ownership of restricted share units
According to Zhitong Finance App News, Jiahe Bio-B (06998) announced that on January 25, 2024, the company will issue 285,000 shares due to selected participants belonging to restricted share units in accordance with the 2021 Restricted Share Unit Plan adopted on June 3, 2021. On the same day, the company issued 8,500 shares at an issue price of HK$0.00155 per share as a result of eligible employees exercising share options under the pre-initial public offering share option scheme.
Jiahe Biotech B (06998) issued 52,500 shares due to ownership of restricted stock units
Jiahe Biotechnology-B (06998) announced on December 22, 2023, since participants were selected based on 2021...
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Analysis
Price Target
No Data
